Literature DB >> 31573153

Ketamine for chronic depression: two cautionary tales

Jeanne Talbot1, Jennifer L. Phillips1, Pierre Blier1.   

Abstract

A growing body of literature has shown the effectiveness of ketamine for treating chronic depression. How long the beneficial effects of repeated ketamine last once infusions are stopped, however, remains largely unknown. Understanding the challenges that ensue after ketamine cessation can help clinicians optimally guide patients who opt for ketamine treatment and minimize the associated risks. In this commentary, we discuss some unexpected data gathered from participants of a pilot study on the effects of adjunctive ketamine infusion for resistant depression.
© 2019 Joule Inc. or its licensors

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31573153      PMCID: PMC6821514          DOI: 10.1503/jpn.190073

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  9 in total

1.  Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.

Authors:  Jennifer L Phillips; Sandhaya Norris; Jeanne Talbot; Meagan Birmingham; Taylor Hatchard; Abigail Ortiz; Olabisi Owoeye; Lisa A Batten; Pierre Blier
Journal:  Am J Psychiatry       Date:  2019-03-29       Impact factor: 18.112

2.  A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation.

Authors:  Yanni Zhan; Bin Zhang; Yanling Zhou; Wei Zheng; Weijian Liu; Chengyu Wang; Hanqiu Li; LiJian Chen; Lin Yu; Martin Walter; Meng Li; Ming D Li; Yuping Ning
Journal:  J Affect Disord       Date:  2019-03-22       Impact factor: 4.839

Review 3.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.

Authors:  Sidney H Kennedy; Raymond W Lam; Roger S McIntyre; S Valérie Tourjman; Venkat Bhat; Pierre Blier; Mehrul Hasnain; Fabrice Jollant; Anthony J Levitt; Glenda M MacQueen; Shane J McInerney; Diane McIntosh; Roumen V Milev; Daniel J Müller; Sagar V Parikh; Norma L Pearson; Arun V Ravindran; Rudolf Uher
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

4.  Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.

Authors:  Ella J Daly; Jaskaran B Singh; Maggie Fedgchin; Kimberly Cooper; Pilar Lim; Richard C Shelton; Michael E Thase; Andrew Winokur; Luc Van Nueten; Husseini Manji; Wayne C Drevets
Journal:  JAMA Psychiatry       Date:  2018-02-01       Impact factor: 21.596

Review 5.  Does ketamine have anti-suicidal properties? Current status and future directions.

Authors:  Rebecca B Price; Sanjay J Mathew
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

6.  Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

Authors:  James W Murrough; Andrew M Perez; Sarah Pillemer; Jessica Stern; Michael K Parides; Marije aan het Rot; Katherine A Collins; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu
Journal:  Biol Psychiatry       Date:  2012-07-27       Impact factor: 13.382

7.  Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.

Authors:  Paulo R Shiroma; Brian Johns; Michael Kuskowski; Joseph Wels; Paul Thuras; C Sophia Albott; Kelvin O Lim
Journal:  J Affect Disord       Date:  2013-10-29       Impact factor: 4.839

Review 8.  The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.

Authors:  Samuel T Wilkinson; Elizabeth D Ballard; Michael H Bloch; Sanjay J Mathew; James W Murrough; Adriana Feder; Peter Sos; Gang Wang; Carlos A Zarate; Gerard Sanacora
Journal:  Am J Psychiatry       Date:  2017-10-03       Impact factor: 18.112

Review 9.  A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.

Authors:  Gerard Sanacora; Mark A Frye; William McDonald; Sanjay J Mathew; Mason S Turner; Alan F Schatzberg; Paul Summergrad; Charles B Nemeroff
Journal:  JAMA Psychiatry       Date:  2017-04-01       Impact factor: 21.596

  9 in total
  4 in total

1.  VA Ketamine Controversies.

Authors:  Eugene Raggi; Srikantha L Rao
Journal:  Fed Pract       Date:  2019-12

Review 2.  Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors:  Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal:  Behav Brain Res       Date:  2020-02-13       Impact factor: 3.332

3.  Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers.

Authors:  Dmitriy Matveychuk; Rejish K Thomas; Jennifer Swainson; Atul Khullar; Mary-Anne MacKay; Glen B Baker; Serdar M Dursun
Journal:  Ther Adv Psychopharmacol       Date:  2020-05-11

4.  A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol.

Authors:  Jennifer L Phillips; Natalia Jaworska; Elizabeth Kamler; Venkat Bhat; Jean Blier; Jane A Foster; Stefanie Hassel; Keith Ho; Lisa McMurray; Roumen Milev; Zahra Moazamigoudarzi; Franca M Placenza; Stéphane Richard-Devantoy; Susan Rotzinger; Gustavo Turecki; Gustavo H Vazquez; Sidney H Kennedy; Pierre Blier
Journal:  BMC Psychiatry       Date:  2020-06-02       Impact factor: 3.630

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.